Analysts forecast that Zoetis Inc (NYSE:ZTS) will post earnings per share (EPS) of $0.82 for the current quarter, Zacks reports. Four analysts have made estimates for Zoetis’ earnings. The lowest EPS estimate is $0.80 and the highest is $0.85. Zoetis posted earnings per share of $0.77 during the same quarter last year, which would indicate a positive year over year growth rate of 6.5%. The company is scheduled to announce its next quarterly earnings report on Thursday, August 1st.
On average, analysts expect that Zoetis will report full-year earnings of $3.48 per share for the current financial year, with EPS estimates ranging from $3.43 to $3.50. For the next financial year, analysts forecast that the business will report earnings of $3.89 per share, with EPS estimates ranging from $3.81 to $3.93. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Zoetis.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.88 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.09. Zoetis had a return on equity of 73.66% and a net margin of 23.47%. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.45 billion. During the same quarter in the previous year, the company posted $0.75 EPS. The business’s revenue was up 6.5% on a year-over-year basis.
A number of research analysts recently weighed in on ZTS shares. BMO Capital Markets upped their price target on Zoetis from $101.00 to $105.00 and gave the stock a “market perform” rating in a research note on Thursday, May 9th. Credit Suisse Group upped their target price on Zoetis from $102.00 to $112.00 and gave the company an “outperform” rating in a report on Tuesday, April 2nd. Zacks Investment Research raised Zoetis from a “sell” rating to a “hold” rating in a report on Saturday, February 16th. Stifel Nicolaus raised Zoetis from a “hold” rating to a “buy” rating and increased their price objective for the company from $97.00 to $110.00 in a report on Monday, March 4th. Finally, SunTrust Banks assumed coverage on Zoetis in a research report on Tuesday, March 19th. They set a “hold” rating and a $100.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $106.67.
In related news, insider Clinton A. Jr. Lewis sold 6,125 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $96.54, for a total value of $591,307.50. Following the sale, the insider now directly owns 57,042 shares of the company’s stock, valued at approximately $5,506,834.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kristin C. Peck sold 11,500 shares of the stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $100.92, for a total transaction of $1,160,580.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 76,716 shares of company stock worth $7,805,856. Corporate insiders own 0.29% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Princeton Global Asset Management LLC raised its holdings in shares of Zoetis by 189.1% in the first quarter. Princeton Global Asset Management LLC now owns 4,192 shares of the company’s stock worth $422,000 after buying an additional 2,742 shares during the last quarter. Nordea Investment Management AB grew its position in Zoetis by 97.9% during the first quarter. Nordea Investment Management AB now owns 487,904 shares of the company’s stock valued at $49,116,000 after buying an additional 241,321 shares during the period. EP Wealth Advisors LLC acquired a new stake in Zoetis during the first quarter valued at $257,000. Dixon Hubard Feinour & Brown Inc. VA grew its position in shares of Zoetis by 2.7% in the first quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 86,950 shares of the company’s stock valued at $8,753,000 after purchasing an additional 2,290 shares during the period. Finally, Horizon Investments LLC acquired a new stake in shares of Zoetis in the first quarter valued at about $311,000. Hedge funds and other institutional investors own 90.30% of the company’s stock.
Shares of NYSE:ZTS traded up $1.28 during midday trading on Wednesday, reaching $111.44. The company’s stock had a trading volume of 1,862,546 shares, compared to its average volume of 2,244,355. The company has a market capitalization of $52.68 billion, a price-to-earnings ratio of 35.60, a P/E/G ratio of 2.75 and a beta of 0.87. The company has a debt-to-equity ratio of 2.84, a current ratio of 4.05 and a quick ratio of 2.79. Zoetis has a fifty-two week low of $78.90 and a fifty-two week high of $111.70.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 19th will be paid a $0.164 dividend. This represents a $0.66 annualized dividend and a yield of 0.59%. The ex-dividend date is Thursday, July 18th. Zoetis’s payout ratio is currently 21.09%.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading: What is total return in investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.